Chiasma Inc. (CHMA) Stock Rating Upgraded by Zacks Investment Research
Chiasma Inc. (NASDAQ:CHMA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Monday. The firm presently has a $2.50 price objective on the stock. Zacks Investment Research’s price target would suggest a potential upside of 19.05% from the company’s current price.
According to Zacks, “Chiasma, Inc. is a biopharmaceutical company. The company’s TPE(R) technology develops oral peptides and other molecules. Its primary product candidate consists of oral octreotide which is in different clinical trial. Chiasma, Inc. is based in Newton, USA. “
Chiasma (NASDAQ:CHMA) opened at 2.10 on Monday. The stock’s market cap is $51.15 million. The stock has a 50 day moving average of $2.48 and a 200-day moving average of $2.73. Chiasma has a 12 month low of $1.85 and a 12 month high of $24.04.
Several large investors have recently made changes to their positions in the stock. Morgan Stanley raised its stake in shares of Chiasma by 1,697.6% in the third quarter. Morgan Stanley now owns 68,867 shares of the company’s stock worth $202,000 after buying an additional 65,036 shares in the last quarter. A.R.T. Advisors LLC bought a new position in shares of Chiasma during the second quarter valued at $441,000. Opaleye Management Inc. raised its position in shares of Chiasma by 115.0% in the second quarter. Opaleye Management Inc. now owns 43,000 shares of the company’s stock valued at $443,000 after buying an additional 23,000 shares during the period. Vanguard Group Inc. raised its position in shares of Chiasma by 25.7% in the second quarter. Vanguard Group Inc. now owns 426,477 shares of the company’s stock valued at $1,233,000 after buying an additional 87,259 shares during the period. Finally, MPM Asset Management LLC raised its position in shares of Chiasma by 1.0% in the second quarter. MPM Asset Management LLC now owns 5,736,296 shares of the company’s stock valued at $16,578,000 after buying an additional 54,752 shares during the period. 58.83% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: “Chiasma Inc. (CHMA) Stock Rating Upgraded by Zacks Investment Research” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another site, it was copied illegally and republished in violation of international copyright and trademark laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2016/11/23/chiasma-inc-chma-stock-rating-upgraded-by-zacks-investment-research.html.
Chiasma Company Profile
Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.
Receive News & Stock Ratings for Chiasma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma Inc. and related stocks with our FREE daily email newsletter.